Related Experiment Videos
Inhaled nitric oxide: more than a selective pulmonary vasodilator
J Gianetti1, S Bevilacqua, R De Caterina
1Ospedale G. Pasquinucci, CNR Institute of Clinical Physiology and G. d'Annunzio University, Chieti, Italy. gianetti@ifc.pi.cnr.it
European Journal of Clinical Investigation
|August 23, 2002
Summary
Inhaled nitric oxide (NO) effectively treats pulmonary hypertension and hypoxia in infants by improving gas exchange. This therapy also shows promise for adults and offers extra-pulmonary benefits, including protection against heart injury.
Area of Science:
- Pulmonary Medicine
- Cardiology
- Neonatology
Background:
- Pulmonary NO deficiency is a significant clinical challenge.
- Inhaled nitric oxide (NO) demonstrates high efficacy due to its diffusion properties.
- NO's selectivity for pulmonary vasculature makes it a targeted therapeutic approach.
Purpose of the Study:
- To evaluate the efficacy of inhaled NO in treating pulmonary hypertension and hypoxia.
- To explore the extra-pulmonary benefits of inhaled NO therapy.
- To assess the safety and effectiveness of inhaled NO in various patient populations.
Main Methods:
- Administration of inhaled nitric oxide (NO) to patients.
- Clinical observation and data collection on gas exchange and ventilation-perfusion matching.
- Analysis of animal models to investigate extra-pulmonary effects.
Main Results:
- Inhaled NO improves gas exchange and ventilation-perfusion matching in infants with pulmonary hypertension or hypoxia.
- Treatment with inhaled NO reduces hospitalization length in infants without severe detrimental effects.
- Evidence suggests beneficial extra-pulmonary effects, including protection against myocardial ischemia-reperfusion injury.
Conclusions:
- Inhaled NO is a viable and efficient treatment for pulmonary NO deficiency, particularly in infants.
- The application of inhaled NO extends to adults with pulmonary hypertension and ARDS.
- Inhaled NO presents promising therapeutic potential beyond pulmonary conditions.